Vimarsana
Biggest News Aggregation in the World

Page 17 - Core Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Core Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Core Lab Today - Breaking & Trending Today

Cardiovascular Clinical Sciences Names Dr. Jing Dai as New Head of Cardiac Core Lab - Vimarsana News

Cardiovascular Clinical Sciences Names Dr. Jing Dai as New Head of Cardiac Core Lab

/PRNewswire/ -- As cardiac imaging becomes more integrated in both clinical practice and research, Cardiovascular Clinical Sciences (CCS) announced today the...

HeartcoR Solutions hires Michael Jandes as director of IT systems - Vimarsana News

HeartcoR Solutions hires Michael Jandes as director of IT systems

Schaumburg, IL (PRWEB) March 06, 2023 -- HeartcoR Solutions announced today that Michael Jandes has been hired as director of IT systems. HeartcoR Solutions

Source: prweb.com
Core Laboratories N.V. (NYSE:CLB) Q4 2022 Earnings Call Transcript - Vimarsana News

Core Laboratories N.V. (NYSE:CLB) Q4 2022 Earnings Call Transcript

Operator: Good morning, and welcome to the Core Laboratories Fourth Quarter 2022 Earnings Call. All participants will be in listen-only mode. .

CORE LABORATORIES N V : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Vimarsana News

CORE LABORATORIES N V : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure. On February 2, 2023, Core Laboratories N.V. held its Q4 2022 earnings call and webcast and made the Webcast available on its website. During the Webcast,... | February 3, 2023

F. Hoffmann-La Roche Ltd: Roche reports good results for 2022 despite decline in demand for COVID-19 products - Vimarsana News

F. Hoffmann-La Roche Ltd: Roche reports good results for 2022 despite decline in demand for COVID-19 products

Basel, 2 February 2023 Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division sales increase